DocWire News
Boris C. Pasche, M.D., Ph.D, FACP, president and CEO of the Barbara Ann Karmanos Cancer Institute and co-inventor of the TheraBionic P1 device, presented the targeted therapy at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in January. He detailed how the device works, the research that led to the discovery of the specific radiofrequency for hepatocellular carcinoma (HCC - advanced liver cancer), and more.
Watch here.
Learn more about liver cancer treatments at Karmanos here.